CLX Investment Company Announces Coverage by The MacReport
TEMECULA, CA, Jul 11, 2006 (MARKET WIRE via COMTEX News Network) -- CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund with holdings in e-learning, global advertising and diagnostic testing markets, today announced that the company is being featured in a profile on The MacReport.net, including a new audio presentation recorded by chief executive officer Robert McCoy. In the presentation, which will also be available as a written transcript, Mr. McCoy reviews the progress of the company's current portfolio holdings: Zonda, Incorporated, ActionView International and eStrategy Solutions.
"CLX will use a variety of venues to bring its story to a wider audience over the next several months, especially as its portfolio companies continue to grow and fulfill their respective business plans," stated Mr. McCoy. "While we have provided frequent information on the development of Zonda, ActionView, and eStrategy Solutions, there are certainly a large number of potential shareholders who have not yet seen the opportunity presented by CLX. Each of our portfolio companies are positioned to increase its value, and we will continue to support these efforts as we concurrently broaden awareness of CLX in the public markets."
The MacReport.Net is an information and media company that provides a Web-based forum for public and private issuers to communicate corporate audio and video news content to the business, financial and investing community through its website.
To view the CLX profile, shareholders are encouraged to visit http://www.themacreport.net and enter the company's name or stock symbol in the appropriate field.
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.
About CLX Investment Company
CLX Investment Company (www.clxinvestments.com) holds a 49% interest in eStrategy Solutions, Inc. (www.estrategysolutions.com), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. Also in the CLX investment portfolio is a 31% equity interest in Zonda, Inc. (www.zondaincusa.com), a privately held company that specializes in test products that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. CLX has invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.
All statements included in this release, including statements regarding potential future plans and objectives, of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
CLX Investment Company Announces Expansion of Global Distribution for Zonda, Inc. With Contracts for Australia and New Zealand
TEMECULA, CA, Jul 14, 2006 (MARKET WIRE via COMTEX News Network) -- CLX Investment Company, Inc. (OTCBB: CLXN) today announced that portfolio investment Zonda Incorporated, which specializes in diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets, has opened new global markets for its products with a distribution agreement for its HandiLab-C chlamydia test in Australia and New Zealand.
The HandiLab-C test for chlamydia is already the subject of distribution contracts in markets across Europe, and is currently distributed in approximately 18 European countries. It is the only over-the-counter test (self testing) for chlamydia that carries the CE mark, which signifies that the product complies with the relevant European Union health, safety, and environmental protection requirements.
"We are pleased to report this new agreement for our Zonda Incorporated portfolio investment," said Robert McCoy, chairman and chief executive officer of CLX Investment Company. "While there has been a focus on markets in Europe for much of the recent distribution of Zonda products, this contract is an important reminder that Zonda is positioning itself to be a worldwide leader of rapid diagnostic tests for multiple large global industries."
"Zonda expects that our HandiLab products will be very well received in the Australia and New Zealand markets, and we look forward the first shipment of the HandiLab-C test for chlamydia to our new distributor," commented Laurie J. Oleksiewicz, president of Zonda Incorporated.
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.
About Zonda, Inc.
Zonda, Inc. (www.zondaincusa.com), in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. The HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use. The gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use, and Zonda is seeking similar approvals for over-the-counter sales of these products. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.
About CLX Investment Company
CLX Investment Company (www.clxinvestments.com) holds a 31% equity interest in Zonda, Inc. (www.zondaincusa.com). Also in the CLX investment portfolio is a 49% interest in eStrategy Solutions, Inc. (www.estrategysolutions.com), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. CLX has invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
Thestockdepot, I would be careful here.CLXN has a history of issuing shares and living of off the investors. They were an energy company changed to an investment company and that has not worked out so far. On 9-10-04 the company had O/S of 2,631,936 and that has ballooned to 118,060,668 on 6-1-06. In 21 months CLXN has issued 115,428,732 shares or 9,619,061 each month. The company only had $209.00 in current assets on their last 10Q. Good luck but I would be very careful here.
At the current price I think CLXN is a good bet. The shares of the company have gone up to the .05 to 09 cent range a couple of times. The outstanding shares have increased for the equity position in the following companies. CLX Investment Company (www.clxinvestments.com) holds a 49% interest in eStrategy Solutions, Inc. (www.estrategysolutions.com), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. Also in the CLX investment portfolio is a 31% equity interest in Zonda, Inc. (www.zondaincusa.com), a privately held company that specializes in test products that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. CLX has invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards. Thanks for your concern, but I usually only buy 2 to 3 hundred thousand shares in a gamble like this. Risk to reward is what I look for.
Logged
Male